Immupharma Regulatory News (IMM)

RNS : FOR IMMEDIATE RELEASE

21 JULY 2016

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

ImmuPharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

√

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

BNY Norwich Union Nominees Limited628,858*

Chase (GA Group) Nominees Limited7,696,271*

State Street Nominees Limited1,413,511*

*denotes direct interest

Chase (GA Group) Nominees Limited627,539

Chase Nominees Limited275,292

Vidacos Nominees Limited528,471

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

19 July 2016

6. Date on which issuer notified:

20 July 2016

7. Threshold(s) that is/are crossed or reached: vi, vii

8% to 7% Change at Direct Interest Level

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

GB0033711010

11,224,776

11,224,776

11,169,942

9,738,640

1,431,302

7.997%

1.175%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Total (A+B+C)

Number of voting rights

Percentage of voting rights

11,169,942

9.172%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Figures are based the revised total number of voting rights of 121,781,219 as per the recent Confirmation of EIS and VCT Qualifying Status and Issue of Equity announcement of 01 March 2016.

14. Contact name:

James Clark, Aviva plc

15. Contact telephone number:

 01603 683853

For further information please contact: